share_log

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $170

Benzinga ·  May 2 14:23

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $164 to $170.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment